[./pages/indexpag.html]
Abeome is an emerging biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve development of monoclonal antibodies for life sciences and clinical medicine.
[./pages/company_overviewpag.html]
[./pages/teampag.html]
[./pages/newspag.html]
[./pages/employmentpag.html]
[./pages/technologypag.html]
[./pages/research_servicespag.html]
[./pages/technologypag.html]
Abeome's DiSH technology is the key to driving unprecedented efficiencies in screening for new targets. Using DiSH, desired monoclonals can be identified using fluorescent-labeled antigens to bind surface- expressed antibodies, making isolation and cloning desired cells significantly easier.
Research and identification of novel/high potential monoclonal antibodies is hampered by a cumbersome, costly and inefficient screening and cloning process.
[./pages/contact_uspag.html]
Copyright © 2006 Abeome Corp. All rights reserved.
[./pages/partneringpag.html]
[./pages/newspag.html]
Click here to see the latest news about Abeome.
[Web Creator] [LMSOFT]